ex4_89.htm


    

      


      Exhibit
4.89

      


      


      Catherine
Soldano-Noble

      Executive
Director, Marketing & Business Development

      Medpace,
Inc.

      4620
Wesley Avenue

      Cincinnati,
OH 45212

      


      


      Re:  Amendment
#2 to the Letter Agreement (“Amendment #2”) for certain initial services for the
Amarin Trial A Study between Amarin Pharma Inc., Amarin Pharmaceuticals Ireland
Limited, and Medpace, Inc. (“Medpace”) dated 24 February 2009 as amended on 5
May 2009 (the “Initial Trial A Services Letter Agreement”).

      


      Dear
Catherine:

      


      The
parties acknowledge that Medpace has already provided certain of the Initial
Trial A Services, and the parties wish to amend Schedule A of the Initial Trial
A Services Letter Agreement to include certain additional activities to be
provided by Medpace prior to the parties entering into the MSA.

      


      This
Amendment #2 is dated as of the date of last signature below.

      


      Defined
terms in this letter shall have the same meanings as given to such terms in the
Initial Trial A Services Letter Agreement unless otherwise defined
herein.

      


      In
consideration of the mutual covenants contained in the Initial Trial A Services
Letter Agreement IT IS NOW
HEREBY AGREED AS FOLLOWS:

      


      
        	
                1.  

              	
                 the
      following activities (the “Additional Activities”)
      will be deemed to be added to Schedule A of the Initial Trial Services
      Letter Agreement:

              


      

      


      
        	
                Item

              	
                Amount

              
	
                Purchase
      of packaging components, project management,

              	
                $125,000

              
	
                design
      of labels

              	 
      


      

      


      


      
        	
                2.  

              	
                the
      Additional Activities shall be deemed to be Initial Trial A Services, as
      such term is defined in the Initial Trial A Services Letter
      Agreement;

              


      

      


      
        	
                3.  

              	
                the
      fees payable for the provision of the Additional Activities shall be
      deemed to be included in the Total Initial Trial A Services Fees and
      accordingly, the Total Trial A Service Fees shall remain unchanged;
      and

              


      

      


      
        	
                4.  

              	
                all
      other provisions of the Initial Trial A Services Letter Agreement shall
      remain unchanged and in full force and
effect.

              


      

      


      Please
confirm your agreement with the above by signing this letter where indicated
below and returning a fully signed version to us.

      


      Yours
sincerely,

      


      Amarin
Pharma Inc.

      


      


      by:___________________________________

      Name:

      


      Title:

      


      Date:

      


      


      Amarin
Pharmaceuticals Ireland Limited

      


      


      by:___________________________________

      Name:

      


      Title:

      


      Date:

      


      


      AGREED
TO:  Medpace Inc.

      


      


      by:___________________________________

      Name:

      


      Title:

      


      Date: